Sharp Edge Labs

Orig3n, Sharp Edge Labs ink drug discovery alliance

Monday, March 28, 2016

ORIG3N, a regenerative medicine provider, and Sharp Edge Labs, a drug discovery and development company focused on genetic disorders, have entered into a drug discovery alliance. As part of the alliance, ORIG3N will make patient-derived cells available to Sharp Edge Labs for use in their drug discovery platform for genetic disorders.

[Read More]